Drugs / MNV-201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06465160 | May 2024 → Dec 2026 expected | myelodysplastic syndrome | Minovia Therapeutics Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06017869 | Jul 2023 → Dec 2026 expected | Pearson syndrome, mitochondrial disease | Minovia Therapeutics Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MNV-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06017869 ↗ |
| Modality | Cell therapy | “MNV-201 is a cell therapy produced by MAT” NCT06017869 ↗ |
| Route | Intravenous | “Single Intravenous Infusion (IV)” NCT06017869 ↗ |